Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 3/20 | 0.48 |
| ▸ | MAOB | P27338 | 3/20 | 0.48 |
| ▸ | CALML3 | P27482 | 6/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 6/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3547446 | 1.00 | MAOA (0.48) | MAOAMAOBCALML3GRM2CYP3A4 | |
| SCHEMBL3548157 | 0.78 | MAOA (0.46) | MAOAMAOBCALML3GRM2CYP3A4 | |
| SCHEMBL3548160 | 0.78 | MAOA (0.46) | MAOAMAOBCALML3GRM2CYP3A4 | |
| SCHEMBL3538460 | 0.77 | MAOA (0.49) | MAOAMAOBCALML3GRM2CYP3A4 | |
| SCHEMBL3541585 | 0.77 | MAOA (0.49) | MAOAMAOBCALML3GRM2CYP3A4 | |
| SCHEMBL3538455 | 0.77 | MAOA (0.49) | MAOAMAOBCALML3GRM2CYP3A4 | |
| SCHEMBL3545245 | 0.76 | MAOA (0.54) | MAOAMAOBCALML3GRM2CYP3A4 | |
| SCHEMBL3545241 | 0.76 | MAOA (0.54) | MAOAMAOBCALML3GRM2CYP3A4 | |
| SCHEMBL3543700 | 0.76 | MAOA (0.51) | MAOAMAOBCALML3GRM2 | |
| SCHEMBL3543693 | 0.76 | MAOA (0.51) | MAOAMAOBCALML3GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1854792-B1 | 1-(2H)-ISOQUINOLONE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2012-12-26 | — | — | EP | disclosed |
| US-7820693-B2 | 1-(2H)-isoquinolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-10-26 | — | — | US | disclosed |
| US-20090030195-A1 | 1-(2H)-ISOQUINOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-01-29 | — | — | US | disclosed |
| EP-1854792-A1 | 1-(2H)-ISOQUINOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030195-A1 | 1-(2H)-ISOQUINOLONE DERIVATIVE | NQO1, NR5A1, SRD5A1 | MAOA 677/4885MAOB 1779/4885CALML3 4208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.